[HTML][HTML] Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
D Planchard, PA Jänne, Y Cheng… - … England Journal of …, 2023 - Mass Medical Soc
Background Osimertinib is a third-generation epidermal growth factor receptor–tyrosine
kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M …
kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M …
Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance
T Araki, S Kanda, H Horinouchi… - Japanese Journal of …, 2023 - academic.oup.com
Osimertinib, a third-generation EGFR TKI, is the standard therapy for previously untreated
EGFR-mutated non-small cell lung cancer patients following the landmark FLAURA study …
EGFR-mutated non-small cell lung cancer patients following the landmark FLAURA study …
New clinical trial design in precision medicine: discovery, development and direction
XP Duan, BD Qin, XD Jiao, K Liu, Z Wang… - Signal Transduction and …, 2024 - nature.com
In the era of precision medicine, it has been increasingly recognized that individuals with a
certain disease are complex and different from each other. Due to the underestimation of the …
certain disease are complex and different from each other. Due to the underestimation of the …
CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor–mutated advanced non–small-cell lung cancer
PA Jänne, D Planchard, K Kobayashi… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE We report CNS efficacy of first-line osimertinib plus chemotherapy versus
osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)–mutated …
osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)–mutated …
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies
V Favorito, I Ricciotti, A De Giglio, L Fabbri… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Current research in EGFR-mutated NSCLC focuses on the management of drug
resistance and uncommon mutations, as well as on the opportunity to extend targeted …
resistance and uncommon mutations, as well as on the opportunity to extend targeted …
New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations
Simple Summary This manuscript focuses on improving the treatment of non-small cell lung
cancer, with actionable gene alterations. The aim is to understand how the treatment with …
cancer, with actionable gene alterations. The aim is to understand how the treatment with …
Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer
Y Xu, H Ji, Y Zhang, L Xiong, B Han, H Zhong… - The …, 2024 - academic.oup.com
Background The efficacy of neoadjuvant treatment with epidermal growth factor receptor
tyrosine kinase inhibitor (EGFR-TKI) monotherapy in patients with stage III-N2 EGFR-mutant …
tyrosine kinase inhibitor (EGFR-TKI) monotherapy in patients with stage III-N2 EGFR-mutant …
Befotertinib—a viable alternative in EGFR-mutant advanced NSCLC?
J Menis, J Remon - The Lancet Respiratory Medicine, 2023 - thelancet.com
The treatment landscape of epidermal growth factor receptor (EGFR)-mutant advanced non-
small-cell lung cancer (NSCLC) has evolved rapidly, and osimertinib, a third-generation …
small-cell lung cancer (NSCLC) has evolved rapidly, and osimertinib, a third-generation …
The design for a phase II, randomized, multicenter study of ctDNA-guided treatment with furmonertinib combined therapy or furmonertinib alone for untreated …
Y Zhang, Z Chen, G Chen, Y Huang, Y Yang… - Clinical Lung Cancer, 2024 - Elsevier
Background Third-generation epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs) have significant antitumor activity to advanced non-small cell lung cancer …
(EGFR-TKIs) have significant antitumor activity to advanced non-small cell lung cancer …
Concordance of Abundance for Mutational EGFR and Co-Mutational TP53 with Efficacy of EGFR-TKI Treatment in Metastatic Patients with Non-Small-Cell Lung …
Y Wang, H Liu, N Yu, X Xiang - Current Oncology, 2023 - mdpi.com
The present study aimed to investigate the influence of the mutation abundance of the
epidermal growth factor receptor (EGFR) and its co-mutation with TP53 on the therapeutic …
epidermal growth factor receptor (EGFR) and its co-mutation with TP53 on the therapeutic …